Stefan Fröhling
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Stefan Fröhling has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Scholl
Department of Internal Medicine III, Ulm University, Ulm, Germany
2 shared publications - Ali Nowrouzi
Department of Translational Oncology, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany
1 shared publication Britta Koch
Department of Internal Medicine III, 2Department of Urology, and 3Institute for Neural Information Processing, Ulm University, 89081 Ulm, Germany
1 shared publicationChristopher M. Hoffmann
Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, 69120 Heidelberg, Germany
1 shared publication- Claudia Regina Ball
Department of Translational Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany
1 shared publication Felicitas Genze
Department of Internal Medicine III, 2Department of Urology, and 3Institute for Neural Information Processing, Ulm University, 89081 Ulm, Germany
1 shared publication
Latest Publications
- Open Access
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S54-S55
134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma
- 1 May 2016
- Published by Elsevier in Molecular Therapy
- Vol. 24, S54-S55
Open Access134. Gene Editing Approaches for Investigating Therapy-Resistance in Soft-Tissue Sarcoma
- Open Access
- 27 March 2012
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 209 (4) , 697-711
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions of STK33 are not yet available. Here, using a mass spectrometry-based screen for STK33 protein interaction partners, we report that the HSP90/CDC37 chaperone complex binds to and stabilizes STK33 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of STK33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in KRAS mutant cells in an STK33-dependent manner. Furthermore, HSP90 inhibitor treatment impaired sphere formation and viability of primary human colon tumor-initiating cells harboring mutant KRAS. These findings provide mechanistic insight into the activity of HSP90 inhibitors in KRAS mutant cancer cells, indicate that the enhanced requirement for STK33 can be exploited to target mutant KRAS-driven tumors, and identify STK33 depletion through HSP90 inhibition as a biomarker-guided therapeutic strategy with immediate translational potential.
- 27 March 2012
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 209 (4) , 697-711
Open AccessTargeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
Previous efforts to develop drugs that directly inhibit the activity of mutant KRAS, the most commonly mutated human oncogene, have not been successful. Cancer cells driven by mutant KRAS require expression of the serine/threonine kinase STK33 for their viability and proliferation, identifying STK33 as a context-dependent therapeutic target. However, specific strategies for interfering with the critical functions of STK33 are not yet available. Here, using a mass spectrometry-based screen for STK33 protein interaction partners, we report that the HSP90/CDC37 chaperone complex binds to and stabilizes STK33 in human cancer cells. Pharmacologic inhibition of HSP90, using structurally divergent small molecules currently in clinical development, induced proteasome-mediated degradation of STK33 in human cancer cells of various tissue origin in vitro and in vivo, and triggered apoptosis preferentially in KRAS mutant cells in an STK33-dependent manner. Furthermore, HSP90 inhibitor treatment impaired sphere formation and viability of primary human colon tumor-initiating cells harboring mutant KRAS. These findings provide mechanistic insight into the activity of HSP90 inhibitors in KRAS mutant cancer cells, indicate that the enhanced requirement for STK33 can be exploited to target mutant KRAS-driven tumors, and identify STK33 depletion through HSP90 inhibition as a biomarker-guided therapeutic strategy with immediate translational potential.